3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with captopril in 1 studies
| Studies (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione) | Trials (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione) | Recent Studies (post-2010) (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione) | Studies (captopril) | Trials (captopril) | Recent Studies (post-2010) (captopril) |
|---|---|---|---|---|---|
| 49 | 7 | 8 | 10,320 | 1,514 | 890 |
| Protein | Taxonomy | 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione (IC50) | captopril (IC50) |
|---|---|---|---|
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 3.6 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.084 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0173 | |
| Succinyl-diaminopimelate desuccinylase | Haemophilus influenzae Rd KW20 | 3.3 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.1004 | |
| Beta-lactamase | Pseudomonas aeruginosa | 5 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.011 | |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
1 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and captopril
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |